Thursday, August 21, 2025 8/21/2025

A novel cell-autonomous role for β-adrenergic receptor signaling in osteoclasts

Award Number: R01AR076349
ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/01/2021
PERIOD OF PERFORMANCE END DATE: 05/31/2026

Group Awards By:

View Award Description

A novel cell-autonomous role for β-adrenergic receptor signaling in osteoclasts - The sympathetic nervous system (SNS) is an important regulator of bone, and may contribute to bone pathology during aging. SNS activity is also heightened in post-menopausal women, causing reduced bone formation by osteoblasts and increased bone resorption by osteoclasts, which leads to bone loss. Large meta- analyses, osteoporosis cohort studies (preliminary data from co-I Dr. Lary) and new prospective trials, consistently show that β-adrenergic receptor (βAR) antagonists (i.e. β-blockers) are associated with reduced fracture risk, increased bone mineral density (BMD), and reduced bone resorption. However, mechanistic studies have focused largely on the osteoblast as the target of SNS activity. Humans and mice have three βARs: β1AR, β2AR and β3AR. The gene encoding β2AR (Adrb2) is highly expressed in bone, which also expresses lower levels of Adrb1, but does not express Adrb3. In mice, Adrb2 deletion in osteoblasts improves bone formation and prevents receptor activator of nuclear factor-kappa B ligand (RANKL)-mediated osteoclast recruitment after stimulation with a β-agonist. In humans, β1-selective β-blockers are used most often, but their selectivity is not absolute, and many still bind β2AR. Propranolol, a non-selective β-blocker, increases BMD in the majority of preclinical studies. Results from our laboratory show that propranolol can limit bone resorption directly in vitro, and in vivo without changing RANKL levels. This is in contrast to the established dogma that osteoblast expression of β2AR regulates osteoclasts only indirectly via RANKL. Our proposed work will resolve the outstanding mechanistic questions of how β1AR and β2AR directly influence osteoclast differentiation and what their contributions are to age- and SNS-related bone loss. We propose a novel hypothesis that βAR signaling in osteoclasts promotes differentiation and resorption and contributes to bone loss in vivo. To fully characterize βAR receptor subtypes and novel signaling mechanisms in osteoclasts, and to determine the contribution of βAR subtypes to in vivo phenotypes of bone density and bone remodeling, we propose a combination of genetic and pharmacologic in vivo and in vitro approaches in the following Specific Aims. Specific Aim 1: We will identify signaling mechanisms activated by specific βARs in osteoclasts. We expect that we will identify novel and established target pathways to test in vivo for efficacy in modulating bone resorption. Specific Aim 2: We will test the relative contributions of osteoclast β1AR and β2AR to SNS- mediated and aging-related bone loss in vivo. The SNS has been implicated in osteoporosis, but the role of βARs in osteoclasts has never been investigated in this condition. We hypothesize that both deletion of β1AR and β2AR, specifically in the osteoclasts, will attenuate βAR agonist-induced and aging-related bone loss in mice. Our work will provide a more complete understanding of the role of SNS signaling in age-related bone loss in vivo, and will lead to studies targeting specific osteoclast βARs and downstream signaling pathways for treatment of bone diseases.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $326,980 )
2025	2025	MAINEHEALTH	110 FREE ST	PORTLAND	ME	04101	CUMBERLAND	USA	Arthritis, Musculoskeletal and Skin Diseases Research	001	5	6/30/2025	NON-COMPETING CONTINUATION	$326,980
2025	2024	MAINEHEALTH	110 FREE ST	PORTLAND	ME	04101	CUMBERLAND	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	4	5/13/2025	SUPPLEMENT FOR EXPANSION	$0
														Subtotal = $326,980

Issue Date FY: 2024 ( Subtotal = $422,705 )
2024	2024	MAINEHEALTH	110 FREE ST	PORTLAND	ME	04101	CUMBERLAND	USA	Arthritis, Musculoskeletal and Skin Diseases Research	001	4	5/22/2024	SUPPLEMENT FOR EXPANSION	$64,939
2024	2024	MAINEHEALTH	110 FREE ST	PORTLAND	ME	04101	CUMBERLAND	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	4	5/17/2024	NON-COMPETING CONTINUATION	$357,766
														Subtotal = $422,705

Issue Date FY: 2023 ( Subtotal = $433,770 )
2023	2023	MAINEHEALTH	22 BRAMHALL ST	PORTLAND	ME	04102	CUMBERLAND	USA	Arthritis, Musculoskeletal and Skin Diseases Research	001	3	5/10/2023	SUPPLEMENT FOR EXPANSION	$64,939
2023	2023	MAINEHEALTH	22 BRAMHALL ST	PORTLAND	ME	04102	CUMBERLAND	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	3	5/10/2023	NON-COMPETING CONTINUATION	$368,831
														Subtotal = $433,770

Issue Date FY: 2022 ( Subtotal = $415,206 )
2022	2022	MAINEHEALTH	22 BRAMHALL ST	PORTLAND	ME	04102	CUMBERLAND	USA	Arthritis, Musculoskeletal and Skin Diseases Research	001	2	9/5/2022	SUPPLEMENT FOR EXPANSION	$50,424
2022	2022	MAINEHEALTH	22 BRAMHALL ST	PORTLAND	ME	04102	CUMBERLAND	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	2	6/2/2022	NON-COMPETING CONTINUATION	$364,782
														Subtotal = $415,206

Issue Date FY: 2021 ( Subtotal = $381,971 )
2021	2021	MAINEHEALTH	22 BRAMHALL ST	PORTLAND	ME	04102	CUMBERLAND	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	1	5/31/2021	NEW	$381,971
														Subtotal = $381,971

Grand Total All Awards = $1,980,632

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A novel cell-autonomous role for β-adrenergic receptor signaling in osteoclasts

Award Number: R01AR076349

ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/01/2021

PERIOD OF PERFORMANCE END DATE: 05/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer